Neuromuscular blocking effect and placental gradient of pipecuronium bromide in elective caesarean section.
We studied the suitability of pipecuronium for maintenance of neuromuscular block during 20 elective Caesarean sections under light general anaesthesia with a rapid-sequence technique facilitated by i.v. suxamethonium 0.6-0.8 mg kg-1. An initial dose of 0.035 mg kg-1 or 0.05 mg kg-1 of pipecuronium provided satisfactory relaxation of similar speed of onset (3.1 +/- 0.3 vs 3.8 +/- 0.6 min, p = 0.25); however the higher dose had a significantly longer duration of action than the lower dose (from injection to recovery to 20% of baseline 13.1 +/- 1.8 vs 39.3 +/- 6.9 min, p < 0.05). A spontaneous recovery of the T1 twitch of the train-of-four to 25% of baseline (residual block 75%) assured rapid antagonism of the residual block with either edrophonium 0.5 mg kg-1 or neostigmine 0.04 mg kg-1. A residual block greater than 80% depression of T1 markedly prolonged the time taken to achieve a satisfactory reversal. Pipecuronium had negligible cardiovascular effects and placental transfer. It had no observable effect on the newborn. In spite of some advantages, we conclude that pipecuronium is a suitable alternative during Caesarean section only when used judiciously in small doses for maintenance of neuromuscular block and recommend that the initial dose be no greater than 0.035 mg kg-1.
Lee
C
C
Department of Anesthesiology, Harbor-UCLA Medical Center, Torrance 90509.
Kwan
W F
WF
Chen
B J
BJ
Tsai
S K
SK
D000293:Adolescent; D000328:Adult; D001034:Apgar Score; D002585:Cesarean Section; D004576:Electromyography; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D009466:Neuromuscular Blocking Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D017300:Pipecuronium / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D010920:Placenta / Q000378:metabolism*; D011247:Pregnancy
D009466:Neuromuscular Blocking Agents; D017300:Pipecuronium